"Dr. Luiz Godoy continued research has enormous implications for disease research and the development of new treatments to combat cancer and other diseases. He is an expert at the pinnacle of his field and his contributions serve as an invaluable resource for the scientific community.”

Gerald N. Wogan, PhD – Professor of Chemistry and Toxicology, MIT, Cambridge, MA

 

 

“Dr. Godoy’s research is also very important to developing new classes of drugs that target cancer, as well as infectious diseases and neurodegenerative disorders”

Joan Mannick, MD, PhD – Executive Director, Novartis Inst. for Biomedical Research, Cambridge, MA

 

 

“Dr. Godoy was the first to demonstrate that using cancer treatment in combination with chemicals that target and kill free radicals causes melanoma cells to be much more vulnerable to chemotherapy, as opposed to using only the anti-cancer drug. His finding holds major clinical relevance to the development of more effective cancer drugs, holds major bearing to expanding scientific knowledge of the way that cancer cell growth is understood today, and has opened new avenues to improve treatment options for melanoma patients.”

Santiago Lamas, MD, PhD – Professor, Universidad Autónoma de Madrid, Spain

 

 

“I am a researcher and medical doctor from the MD Anderson Cancer Center in Texas. My work focuses on cancer research with a strong emphasis on melanoma, the most deadly form of skin cancer. I share very close research interests with Dr. Godoy and my scientific findings largely depend on his contributions to the field.”

 

Elizabeth A. Grimm, MD, PhD – Professor of Medicine, MD Anderson Cancer Center, Houston, TX

 

 

“As a fellow researcher in his field I see his work to be of very high value to the overall healthcare of the United States and the world.”

 

Jonathan Stamler, MD - Professor of Medicine and Biochemistry, Case Western Reserve University, Cleveland, OH